We Have a Track Record of Creating Value for Our Partners
Selected Publicly Announced Investments
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Humacyte_2x.png)
Humacyte is developing universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine.
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Helsinn_2x.png)
Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. The Company is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and a focus on cancer therapeutics and rare diseases.
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Zealand_2x.png)
Zealand Pharma is a biotechnology company focused on the discovery and development of peptide-based medicines. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Centessa_2x.png)
Centessa Pharmaceuticals is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Centessa’s programs span discovery-stage to late-stage development and cover a range of high-value indications.
![](https://www.oberlandcapital.com/wp-content/uploads/2023/06/Mirum_2x-2.png)
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution, which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome three months of age and older.
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Axogen_2x.png)
Axogen is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures.
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Esperion_2x.png)
Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol ("LDL-C").
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Northstar_2x-rev.png)
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company focused on advancing patient care by providing diagnostic and therapeutic radioisotopes, novel radiopharmaceuticals and customized radiopharmaceutical development services.
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Invitae_2x.png)
Invitae is a medical genetics company offering high-quality, comprehensive, affordable genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, and rare disease.
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Impact_2x.png)
Acquired by Celgene Corporation.
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Agenus_2x-1.png)
Agenus is an immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies and adjuvants.
![](https://www.oberlandcapital.com/wp-content/uploads/2023/09/Oxford_2x.png)
Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
Referenced companies do not represent an entire fund or portfolio.